profit from every $100 of sales.
$0$100
Galapagos N.V. Sponsored ADR
$33.98+0.15% today
-1.5% in 1 year
1-year low $26.081-year high $34.64
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $6.33 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Galapagos N.V. Sponsored ADR sold, what it kept, and what it did with the cash.
Sales went from €241 million in 2022 to €1.11 billion in 2025, with €321 million of profit last year.
SalesProfit
Galapagos N.V. Sponsored ADR vs. similar companies
Galapagos N.V. Sponsored ADR grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Galapagos N.V. Sponsored ADR | 6.3× · Cheap | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Galapagos N.V. Sponsored ADR's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 241 | 240 | 276 | 1,112 | |
| 241 | 240 | 241 | 1,083 | |
| -131 | -88 | -188 | 501 | |
| 4 | 51 | 43 | 359 | |
| -218 | 212 | 74 | 321 | |
| -3.32 | 3.21 | 1.12 | 4.87 | |
| 100.0% | 100.0% | 87.4% | 97.3% | |
| -54.3% | -36.8% | -68.3% | 45.1% | |
| -90.4% | 88.3% | 26.9% | 28.9% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 4,734 | 4,357 | 4,136 | 3,407 |
| Cash | 508 | 167 | 64 | 88 |
| Total debt | 22 | 10 | 12 | 7 |
| Total liabilities | 2,208 | 1,562 | 1,239 | 171 |
| 2,526 | 2,796 | 2,897 | 3,236 | |
| 66 | 66 | 66 | 66 | |
| -1.9% | 0.2% | -0.1% | 7.4% | |
| -8.6% | 7.6% | 2.6% | 9.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -501 | -406 | -320 | -257 | |
| 37 | 19 | 82 | 14 | |
| -537 | -425 | -402 | -271 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 89 | 57 | 20 | 24 |
Valuation
- 6.3×
- –
- –
- 0.5×
- 1.8×
- –
- 5.4×
- -13.4%
- 15.8%
- 0.0%
Profitability
- 97.3%
- 45.1%
- 28.9%
- 38.1%
- 18.2%
- 9.9%
- 16.9%
- 14.5%
- 18.2%
- 29.5%
Growth
- +66.4%
- –
- –
- –
- –
Financial health
- -0.2×
- 0.00
- 0.2%
- –
- 30.48
- 30.30
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 946
Top 4%of 872
Top 5%of 565
Top 9%of 867
Bottom 8%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.25 | -0.94 | +126.2% |
| Feb 23, 2026 | 13.90 | -0.13 | +11,077.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
68Pass
Benjamin Graham
100Pass
Philip Fisher
79Pass
Peter Lynch
100Pass
Joel Greenblatt
78Pass
Charlie Munger
67Pass
Terry Smith
64Pass
Questions about Galapagos N.V. Sponsored ADR
Is Galapagos N.V. Sponsored ADR a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Galapagos N.V. Sponsored ADR AI analysis
What does Galapagos N.V. Sponsored ADR do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. It is in Biotechnology.
Does Galapagos N.V. Sponsored ADR pay a dividend?
No. Galapagos N.V. Sponsored ADR does not pay a dividend at the moment.
Is Galapagos N.V. Sponsored ADR stock halal?
No. Galapagos N.V. Sponsored ADR does not pass our halal screen: its cash and term deposits are about three-quarters of its market value, above the 33% limit. How we check
How has Galapagos N.V. Sponsored ADR stock done over the past year?
Down 1.5% over the past twelve months, to $33.98. It traded between $26.08 and $34.64, close to its high.
Who are Galapagos N.V. Sponsored ADR's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Galapagos N.V. Sponsored ADR's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.